… of physiologically based pharmacokinetic (PBPK) model to predict ceftazidime exposure in
healthy volunteers and subjects with renal impairment. A full PBPK model of ceftazidime was …

… We examined when age-related differences of investigated pharmacokinetic parameters
changed more than expected from interindividual variability defined as the 1.25-fold interval (…

… power to detect any differences in risk implied by the models. The objective of this …
pharmacokinetic and pharmacodynamic models in epidemiological studies. Occupational exposures …

… in differences among individuals in the biologically effective tissue dose associated with a
given environmental exposure (pharmacokinetics… in dosimetry for in vivo exposures. However, …

… trials used to develop the pharmacokinetic model, yielded comparable results. Adaptive
procedures allow shrinkage of the observed exposure distribution around the target range …

… Although there are established default methods (uncertainty factors for noncancer effects
and safety factors) used to account for species differences in exposure (pharmacokinetics) and …

… Understanding the influence of ethnicity on drug exposure is key to patient safety and could
… ability of physiologically-based pharmacokinetic modelling to predict exposure of CYP2C19 …

… were clearly bioinequivalent, statistically significant differences of adverse effects among …
In the present study a pharmacokinetic–pharmacodynamic (PK–PD) model is proposed to …

… based pharmacokinetic (PBPK) models are particularly useful for simulating exposures to …
When using PBPK models to adjust for pharmacokinetic differences between species, a …

… In the absence of in vitro kinetic data describing the pharmacokinetics in carriers of CYP2C8…
impact of these genotypes (accounting for differences in enzyme abundance) determined in …